Aimwell is the adversarial validation layer that sits between AI-generated science and your accountability. Four independent agents audit every brief. One consensus verdict: PROCEED DELAY KILL.
PROCEED. DELAY. KILL. — Before the FDA decides for you.
Validated Against 40,000+ Historical Regulatory Decisions · Aligned With ICH E9(R1) Statistical Principles · FDA CDER Guidance-Informed Methodology · ClinicalTrials.gov Integrated Data
This is not a white paper about AI risk. It is the operational methodology behind the PROCEED / DELAY / KILL verdict system — ICH E9(R1) aligned, built on 40,000+ historical FDA decisions, and calibrated quarterly as new regulatory data is published.
REGTECH is not where the industry is going. It is where the FDA's own internal capabilities are already arriving. The question is whether your AI-generated submissions will survive that scrutiny when it reaches yours.
Members receive: live audit runs · verdict history · regulatory signal monitoring · board-ready packages · full corpus access
The systems your organization depends on were not built for this environment. They were built for a slower world with fewer signals, fewer threats, and more time to react. That world no longer exists. And the gaps in your intelligence are already costing you — you just haven't traced the losses back to their source yet.
The cost is not inefficiency. The cost is being wrong. Wrong about a filing timeline. Wrong about a competitor. Wrong about a regulatory shift. The organizations that pay for broken intelligence don't know they're paying — until the board asks why.
An FDA guidance revision changes your lead indication's endpoint structure. Your team learns about it from a competitor's earnings call. The filing timeline you presented to the board last quarter is now wrong.
Your regulatory team sees one version of the landscape. BD sees another. The executive suite sees a third. No one knows whose version is correct. All three are making decisions with confidence in their own data.
A competitor advances a Phase II asset in your target indication. They announced it at a conference your team did not attend and did not monitor. You learn about it 23 days later. Your board asks why.
Your team uses a general-purpose AI tool to summarize a regulatory landscape. It fabricates a citation. That fabrication enters a board presentation. No containment layer exists. No one catches it until the damage is done.
Your VP of Regulatory Affairs leaves. With her goes 14 months of institutional context — why certain decisions were made, which advisory boards gave which signals, the rationale behind your filing strategy. Gone.
Every strategic decision your organization makes is only as good as the intelligence behind it. Without continuous synthesis, your executive team is making $50M decisions on $500 worth of information.
These are not hypothetical risks. They are happening inside your organization right now.
You don't notice the mistake when it happens. You notice it when it's too late.
The system that eliminates this is already running. It is called the AIMN intelligence suite.
Right now, Cortex is ingesting regulatory filings, scanning clinical trial updates, and cross-referencing competitive movements across your therapeutic landscape. It is not waiting for a query. It is not idle between sessions. It is actively watching everything your team cannot.
It doesn't just inform. It learns how your organization thinks, what it prioritizes, and where its blind spots form. Then it adapts.
Every signal is classified. Every signal is scored. Every signal is explained. Every signal is tracked. Every decision is recorded, evaluated, and improved. This creates something most organizations lack: institutional memory of intelligence. The longer it runs, the sharper it gets. The window for competitors without this narrows every day.
AIMN:ATLAS is a real-time global biopharma intelligence map — 65 tracked companies, 11 regulatory agency heat zones, and a continuous signal feed from AIMN Archive, OpenFDA, and ClinicalTrials.gov, unified through three proprietary intelligence layers.
The Adversarial System
Each agent audits independently. No collaboration. No confirmation bias. The consensus engine applies override logic: any single KILL vote forces a minimum DELAY.
Agent 01 — Regulatory Agent
Reads research briefs the way an FDA reviewer reads an IND or NDA. Flags missing sensitivity analyses, endpoint definitions misaligned with current guidance, inadequate alpha allocation, missing subgroup analyses, and biomarker validation gaps. Trained on advisory transcripts and ICH guidance.
Agent 02 — Competitive Agent
Maps the competitive landscape around the asset in real time. Projects competitor Phase readouts, mechanism-of-action overlap, first-in-class vs. best-in-class positioning, and partnership/M&A signals that accelerate competitive threat. Answers: what does the competitive landscape look like at approval — not today?
Agent 03 — Trial Failure Agent
Evaluates trial design, not hypothesis. Detects biomarker stratification gaps, interim futility misses, enrollment-rate overestimation (typical overestimate: 40–60% in narrow populations), surrogate endpoints the FDA has deprioritized, and site activation blindspots.
Agent 04 — Capital Risk Agent
Does not say “this is risky.” Says: $340M at 31% probability if the enrollment assumption fails. Outputs probability-weighted capital loss scenarios, stage-gate recommendations, royalty/licensing NPV adjustments, and investor exposure modeling for term sheet negotiations.
Shadow Lab
Delivery system. Three intake methods.
Total wall time: 15–30 seconds
Direct brief input via the interface
Programmatic submission via REST endpoint
Automated relay from partner AI platform
The market built powerful tools to generate candidates, file documents, and run trials. It built nothing to audit them. Until now.
We do not compete with AI drug discovery platforms. We audit them.
These are not edge cases. They are the failure modes your current stack does not catch.
The FDA doesn’t accept ‘our AI model was confident.’ Our agent simulates the reviewer’s response before you submit.
Aimwell runs an adversarial simulation of the FDA reviewer’s read of your submission — surfacing objection vectors, regulatory gaps, and section-level risk before the package leaves your team.
FDA rejection scenario · guidance citation · section number · recommended remediationYou’re licensing against today’s landscape. We show you what it looks like at approval.
Aimwell projects competitive standing forward to projected approval date — modeling pipeline entrants, label evolution, and market share assumptions embedded in the deal thesis.
Competitive displacement risk · pipeline threat index · deal assumption stress test · PROCEED / DELAY / KILL verdictThe deck shows upside. We quantify the downside scenarios the sponsor did not include.
Aimwell reconstructs the assumptions behind the sponsor’s projections and runs adversarial scenarios — regulatory delay, competitive entry, enrollment failure — with probability-weighted impact on IRR.
Downside scenario map · assumption audit · IRR sensitivity by scenario · audit trail for LP reportingYour AI-generated clinical brief enters a trial. Our agent found the enrollment assumption was off by 47%. Three months in, the IDMC halts the trial.
Aimwell audits AI-generated trial designs and clinical briefs before activation — stress-testing enrollment assumptions, endpoint definitions, and inclusion/exclusion criteria against historical site and population data.
Enrollment viability score · endpoint risk flag · site feasibility delta · protocol amendment riskThese scenarios are not hypothetical. They are the failure modes adversarial validation exists to prevent.
This is how decisions will be made in biopharma. The only question is whether your organization builds this capability now or inherits the cost of not having it.
Global data streams across regulatory, clinical, competitive, and research domains. Automated. Continuous. Private. Your competitors' signals are already being captured.
Signals are classified, scored, deduplicated, and mapped into relevance to your therapeutic areas. AIMN:SCOUT autonomously researches entities, extracts pipeline signals, and generates structured intelligence briefings — no analyst intervention required. Without this, your team is making sense of noise manually.
Conversational intelligence that prioritizes what matters, surfaces blind spots, tracks decisions, and evolves context. The proprietary multi-agent orchestration layer that routes signals through SCOUT, validates through FHIN contributors, and surfaces intelligence through AIMN:ATLAS. This is the layer that replaces fragmented intelligence.
Human validation where certainty is required. Hallucination containment. Fact grounding. Without this, fabricated data enters your decision chain.
Every interaction improves future intelligence. Corrections compound. Organizations without this start from zero every time.
Every layer accountable. Every output labeled. Every claim traceable. No other system does all six. If even one layer is missing, unverified intelligence reaches your executives.
FDA filings, ClinicalTrials.gov, PubMed, SEC disclosures, USPTO patents, global news, conference proceedings. Automated. Continuous. Private.
AIMN:SCOUT parses, deduplicates, entity-resolves, and maps to your therapeutic areas. Raw signal becomes structured intelligence.
Every claim gets provenance tracing, reliability scoring, confidence tags, and freshness verification. You see what is verified and what is speculative.
Cross-reference. Claim extraction. Fact grounding. Issue flagging. The layer that prevents fabricated intelligence from reaching your executives.
AIMN:ATLAS renders the full intelligence picture in real time — 65 companies, 11 regulatory zones, live signal feed, 90-day PULSE forecasts. Executive summaries. BD landscapes. Regulatory zone analysis.
Every correction, decision, and analyst review compounds. Your intelligence system gets smarter over time. When people leave, the knowledge stays.
Private · Continuous · Validated · Hallucination-Contained · Decision-Ready
Every output is labeled. Every insight includes a reasoning path, source traceability, and confidence level. You never have to wonder where a conclusion came from or how certain it is.
Because when intelligence enters the decision chain without provenance, the organization inherits the risk of whatever that intelligence got wrong. This is already happening at most biopharma organizations. They just haven't audited the chain yet.
What No One Is Telling You
You already have access to information. Your team reads the journals. They attend the conferences. They monitor the databases.
What you don't have is:
Prioritization
Which of the 400 signals this week actually changes a decision?
Alignment
Is every team operating on the same version of the truth?
Continuity
Does your intelligence survive a single departure?
Memory
Does your organization remember why it made the decisions it made last quarter?
That's where decisions break down. And it is already happening.
Anonymized intelligence outcomes from active deployments. Every signal below was invisible before Cortex. Every one of these is happening in your market right now. The question is whether your organization sees them.
Cortex identified an endpoint restructuring in oncology guidance 18 days before the client's regulatory team was briefed by their consultants. Filing timeline was adjusted before it became a board-level problem.
A direct competitor advanced a PROTAC degrader into Phase II in the client's target indication. The signal was in a conference abstract and an SEC filing. Cortex surfaced it within 4 hours. BD strategy was revised the same week.
Key opinion leaders began questioning the tolerability profile of the client's drug class. The signal was distributed across conference commentary, social channels, and analyst notes. Cortex synthesized the pattern 3 weeks before the analyst downgrade.
Different teams operate on different datasets, different timelines, and different interpretations. This creates invisible risk. Not the kind that triggers an alert. The kind that compounds silently until two teams present contradictory strategies to the same board, based on intelligence that was never reconciled.
Cortex is already identifying these patterns in active deployments. It sees when two teams are operating on different versions of the same truth. It surfaces the contradiction before it reaches the boardroom. It creates alignment not through meetings, but through shared, verified, continuously updated intelligence. Without this, the misalignment compounds silently until it becomes a strategic failure.
Competitive Edge
AIMWELL Cortex is surfacing emerging patterns, contradictions, and weak signals before they become market movement. The organizations that act on intelligence before it becomes consensus define the next cycle. The ones that wait inherit whatever position is left. This is how decisions will be made in biopharma. The transition is already underway.
Every week, your organization synthesizes intelligence manually. Your regulatory team tracks guidance changes in spreadsheets. Your BD team hears about competitor moves at conferences — after the market has already priced them in. This is not a technology gap. This is a survival gap.
The organizations that dominate the next cycle of biopharma will not be the ones with the best molecules. They will be the ones with the best information architecture around those molecules. This is not a future state. This transition is happening now. The organizations that move first will set the standard everyone else is forced to meet.
Biopharma spends $140 billion annually on outsourced intelligence, consulting, and advisory. Most of it is unstructured, unverifiable, and non-compounding. The industry is paying enterprise prices for artisanal processes.
AimwellBio is not competing with dashboards. It is replacing the entire unstructured intelligence supply chain with a private, validated, continuously learning operating system. The TAM is not a feature market. It is the decision infrastructure layer beneath every biopharma organization on earth. The category is forming now. The first system to establish institutional trust at scale becomes the standard. That window is measured in quarters, not years.
Ministries operate in environments where external dependencies create risk, global signals affect national outcomes, and delayed insight impacts population health. Cortex enables sovereign intelligence independence. Nations that build this capability now control their pharmaceutical future. Those that wait will license it from the nations that moved first.
The crisis facing biopharma intelligence is documented, cited, and accelerating. These briefings map the full scope — from FDA hallucinations to sovereign liability gaps — and why the organizations that move first will define the standard.
Final Position
Fewer blind spots. Faster clarity. Stronger decisions. AIMWELL exists for environments where missing something is not acceptable. The organizations already using this system are compounding an intelligence advantage every day. The gap between them and everyone else is widening right now.
Deployments begin with a guided intelligence assessment. Enterprise, institutional, and sovereign inquiries welcome.